Q4 25 EPS
$2.71
MISS 19.10%
Est. $3.35
Q4 25 Revenue
$16.62B
BEAT +1.22%
Est. $16.42B
vs S&P Since Q4 25
-9.9%
TRAILING MARKET
ABBV -3.6% vs S&P +6.4%
Full Year 2025 Results
FY 25 EPS
$10.00
BEAT +0.64%
Est. $9.94
FY 25 Revenue
$61.16B
BEAT +0.33%
Est. $60.96B
Market Reaction
Did ABBV Beat Earnings? Q4 2025 Results
AbbVie closed out 2025 on a mixed note, posting a headline earnings miss that masked genuinely strong revenue momentum underneath. Fourth-quarter adjusted diluted EPS came in at $2.71, falling well short of the $3.35 consensus estimate by 19.10%, lar… Read more AbbVie closed out 2025 on a mixed note, posting a headline earnings miss that masked genuinely strong revenue momentum underneath. Fourth-quarter adjusted diluted EPS came in at $2.71, falling well short of the $3.35 consensus estimate by 19.10%, largely due to $0.71 per share in acquired IPR&D and milestones charges tied to the company's pipeline investments. Revenue, however, told a more encouraging story, reaching $16.62 billion for the quarter, up 10.0% year over year and edging past the $16.42 billion consensus by 1.22%. The growth engine was AbbVie's immunology franchise, where Skyrizi surged 32.5% to $5.01 billion in Q4, more than compensating for Humira's continued 25.9% decline to $1.25 billion. Some analysts have flagged concerns about growth trajectories beyond 2028 as competitive pressures loom, but management signaled confidence in near-term momentum by guiding 2026 adjusted diluted EPS to a range of $14.37 to $14.57, reflecting expectations for meaningful earnings acceleration in the year ahead.
Key Takeaways
- • Skyrizi revenue growth of 32.5% in Q4, becoming AbbVie's largest product at $5.0 billion in quarterly revenue
- • Rinvoq revenue growth of 29.5% in Q4 driven by both U.S. and international expansion
- • Neuroscience portfolio growth of 17.9% led by Vraylar, Botox Therapeutic, and migraine franchise
- • Strong operational execution offsetting continued Humira biosimilar erosion
- • Qulipta grew 42.6% in Q4 as migraine franchise continues rapid expansion
ABBV YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
ABBV Revenue by Segment
With YoY comparisons, source: SEC Filings
ABBV Revenue by Geography
With YoY comparisons, source: SEC Filings
“2025 was another outstanding year for AbbVie. We delivered record net sales in just the second full year following the U.S. Humira loss of exclusivity, underscoring the strength of our diversified growth platform. We also advanced promising new treatments for patients while enhancing the breadth and depth of our pipeline with strategic investments.”
— Robert A. Michael, Q4 2025 Earnings Press Release
ABBV Earnings Trends
ABBV vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
ABBV EPS Trend
Earnings per share: estimate vs actual
ABBV Revenue Trend
Quarterly revenue: estimate vs actual
ABBV Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | $2.65 | — | $15.00B | +1.93% |
| Q4 25 MISS FY | $3.35 | $2.71 | -19.10% | $16.62B | +1.22% |
| FY Full Year | $9.94 | $10.00 | +0.64% | $61.16B | +0.33% |
| Q3 25 BEAT | $1.78 | $1.86 | +4.23% | $15.78B | +1.23% |
| Q2 25 BEAT | $2.91 | $2.97 | +2.14% | $15.42B | +2.61% |
| Q1 25 BEAT | $2.40 | $2.46 | +2.62% | $13.34B | +3.27% |